Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/03/2012US20120107377 Particulate composition and pharmaceutical composition containing the same
05/03/2012US20120107376 Method for improving bioavailability of latanoprost
05/03/2012US20120107374 Coenzyme q10-containing composition
05/03/2012US20120107370 Methods and compositions for treating hiv-associated diarrhea
05/03/2012US20120107367 Site-Specific Intestinal Delivery of Adsorbents, Alone or in Combination with Degrading Molecules
05/03/2012US20120107365 Films and particles
05/03/2012US20120107362 Neurotoxins exhibiting shortened biological activity
05/03/2012US20120107342 Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method
05/03/2012US20120107331 Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
05/03/2012US20120107329 EGFR and PAR2 Regulation of Intestinal Permeability
05/03/2012US20120107328 Gamma secretase modulators
05/03/2012US20120107323 Kinase protein binding inhibitors
05/03/2012US20120107319 Pharmaceutical compositions comprising antibodies binding to the intracellular domain of EBV (Epstein-Barr virus) latent membrane protein-1 (LMP1)
05/03/2012US20120107317 Use of cytoplasmic c-myc for regulating immune responses
05/03/2012US20120107313 Mammalian receptor proteins; related reagents and methods
05/03/2012US20120107312 Combinations for the Treatment of Diseases involving Cell Proliferation
05/03/2012US20120107309 Polymorphism in k-ras 3' untranslated region associated with clinical outcomes of cancer treatments independent of k-ras mutation status
05/03/2012US20120107308 Gene expression levels of egfr, vegfr2, and ercc1 associated with clinical outcomes of chemotherapy
05/03/2012US20120107307 Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
05/03/2012US20120107304 Combination therapy in treatment of oncological and fibrotic diseases
05/03/2012US20120107303 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
05/03/2012US20120107300 Cannabinoid Compositions and Methods
05/03/2012US20120107282 Neural stem cell composition capable of treating cancer and method of treatment
05/03/2012US20120107276 Anti-Arenaviral Compounds
05/03/2012US20120107275 Fused heterocyclic derivatives and methods of use
05/03/2012US20120107274 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
05/03/2012US20120107273 New piperazine compound and use thereof as a hcv polymerase inhibitor
05/03/2012US20120107272 Synthetic methods and derivatives of triphosphate oligonucleotides
05/03/2012US20120107271 Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
05/03/2012US20120107269 Thiophene derivatives
05/03/2012US20120107255 Photostabilization of cholecalciferol with alkoxycrylene compounds
05/03/2012US20120107252 Method for forming cyclodextrin polymer and lipophilic compound emulsions, resulting emulsions, and compositions including said emulsions
05/03/2012US20120107251 Oregano oral care compositions and methods of use thereof
05/03/2012US20120107250 Abuse-proofed dosage form
05/03/2012US20120107247 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their Use as Diagnostic Reagents and Vaccines
05/03/2012US20120107242 Nucleic acid-mediated shape control of nanoparticles for biomedical applications
05/03/2012US20120107241 Particles for Inhalation Having Sustained Release Properties
05/03/2012US20120107230 Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide Analogs
05/03/2012US20120107229 Novel nano-probes for molecular imaging and targeted therapy of diseases
05/03/2012US20120104039 Medicament/Dosimeter Combination Packaging
05/03/2012DE102010050449A1 Verwendung von Etacrynsäure zur Behandlung von Lebensmittelempfindlichkeitsstörungen Use of ethacrynic acid for the treatment of food hypersensitivity disorders
05/03/2012DE102010049877A1 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate 7 - ((1,2,3) triazol-4-yl) pyrrolo (2,3) pyrazine
05/03/2012DE102010049708A1 Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe Oral pharmaceutical film formulation for bitter tasting drugs
05/03/2012CA2856153A1 Peptide
05/03/2012CA2853974A1 Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomericallyp ure compositions and methods
05/03/2012CA2847197A1 Treatment for dupuytren's disease
05/03/2012CA2828238A1 Therapeutic use of dimiracetam to prevent the hand & foot syndrome caused by sorafenib
05/03/2012CA2817068A1 Therapeutic solution concentrate
05/03/2012CA2816570A1 Enhanced cancer treatment and monitoring using recombinant vectors
05/03/2012CA2816564A1 Inflammatory disease
05/03/2012CA2816420A1 Compositions of (-)-17-(cyclobutylmethyl) morphinan-3, 14-diol
05/03/2012CA2816418A1 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
05/03/2012CA2816416A1 Methods and compositions for treating hiv-associated diarrhea
05/03/2012CA2816321A1 Compositions and methods for inhibition of pcsk9 genes
05/03/2012CA2816291A1 Novel anti-dr5 antibody
05/03/2012CA2816285A1 Naphthyridine derivative
05/03/2012CA2816203A1 Aripiprazole compositions and methods for its transdermal delivery
05/03/2012CA2816188A1 Substituted phenoxypyridines
05/03/2012CA2816171A1 Liposomal drug composition containing a polymeric guanidine derivative
05/03/2012CA2816104A1 Deuterium enriched rasagiline
05/03/2012CA2816088A1 Metalloenzyme inhibitor compounds
05/03/2012CA2816084A1 Phenylketone carboxylate compounds and pharmaceutical uses thereof
05/03/2012CA2816056A1 Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
05/03/2012CA2816054A1 Methods and compositions suitable for promoting healthy skin
05/03/2012CA2816022A1 Quinazoline derivatives, compositions, and uses related thereto
05/03/2012CA2815960A1 Tau imaging probe
05/03/2012CA2815910A1 Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
05/03/2012CA2815710A1 Quinazoline derivatives
05/03/2012CA2815634A1 Intermediate compounds and process for the preparation of fingolimod
05/03/2012CA2815632A1 Compositions and methods for specific cleavage of exogenous rna in a cell
05/03/2012CA2815582A1 Treatment of mecp2-associated disorders
05/03/2012CA2815542A1 Use of a spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is useful for preventing and/or treating multiple sclerosis
05/03/2012CA2815537A1 Inhibitors of hepatitis c virus
05/03/2012CA2815536A1 Boronates as arginase inhibitors
05/03/2012CA2815501A1 23-yne-vitamin d3 derivative
05/03/2012CA2815436A1 Ophthalmic compositions
05/03/2012CA2815392A1 Maple tree-derived products and uses thereof
05/03/2012CA2815170A1 Pyridine derivative and medicinal agent
05/03/2012CA2815169A1 N1/n2-lactam acetyl-coa carboxylase inhibitors
05/03/2012CA2814951A1 Hypersulfated disaccharides to treat elastase related disorders
05/03/2012CA2814907A1 Crystalline form of 13-[(n-tert-butoxycarbonyl)-2'-o-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin iii
05/03/2012CA2814905A1 Indole derivatives and process for their preparation
05/03/2012CA2814888A1 Medicinal product comprising hydromorphone, with improved shelf-life
05/03/2012CA2814846A1 Cyclic amine substituted oxazolidinone cetp inhibitor
05/03/2012CA2814768A1 Oxazoline and isoxazoline derivatives as crac modulators
05/03/2012CA2814752A1 Diazeniumdiolate heterocyclic derivatives
05/03/2012CA2814703A1 Hiv integrase inhibitors
05/03/2012CA2814439A1 Dosing regimes for the treatment of ocular vascular disease
05/03/2012CA2814436A1 Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
05/03/2012CA2814411A1 Polymorphs of febuxostat
05/03/2012CA2814371A1 Use of malononitrilamides in neuropathic pain
05/03/2012CA2814230A1 Formulations and methods for attenuating respiratory depression induced by opioid overdose
05/03/2012CA2814120A1 Novel anti-cancer agents
05/03/2012CA2813433A1 Trimegestone (tmg) for treatment of preterm birth
05/03/2012CA2811854A1 Diterpenoid derivatives endowed of biological properties
05/03/2012CA2811805A1 Solid dispersions containing an apoptosis-inducing agent
05/03/2012CA2804797A1 Therapeutic compositions for diabetic symmetrical polyneuropathy and/or tactile allodynia
05/02/2012EP2447285A2 Low molecular weight heparin composition and uses thereof
05/02/2012EP2447275A1 Methods and reagents for treatment of age-related macular degeneration
05/02/2012EP2447272A1 2'-Fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors
1 ... 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 ... 7860